Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (Q64119002)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

title

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Susan Halabi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

author name string

Suanna S Bruinooge

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Elizabeth Garrett-Mayer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Ajjai Alva

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Katherine A Janeway

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Philip J Stella

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Emile Voest

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Kathleen J Yost

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Jane Perlmutter

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Navin Pinto

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Edward S Kim

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Richard L Schilsky

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

language of work or name

English

0 references

publication date

11 July 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

published in

JCO Precision Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

volume

2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

17 April 2020

issue

2

0 references

page(s)

1-14

0 references

cites work

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

International uniform response criteria for multiple myeloma.

1 reference

12 December 2020

Proper inference from Simon's two-stage designs

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

1 reference

12 December 2020

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma

1 reference

12 December 2020

Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation

1 reference

12 December 2020

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

1 reference

12 December 2020

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

1 reference

12 December 2020

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

1 reference

12 December 2020

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

1 reference

12 December 2020

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

1 reference

12 December 2020

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

1 reference

12 December 2020

Prospective enterprise-level molecular genotyping of a cohort of cancer patients

1 reference

12 December 2020

A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer.

1 reference

12 December 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

12 December 2020

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

1 reference

12 December 2020

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

1 reference

12 December 2020

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

1 reference

12 December 2020

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

1 reference

12 December 2020

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

1 reference

12 December 2020

A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs

1 reference

12 December 2020

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

1 reference

12 December 2020

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

1 reference

12 December 2020

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

1 reference

12 December 2020

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

1 reference

12 December 2020

The evidence framework for precision cancer medicine.

1 reference

12 December 2020

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

1 reference

12 December 2020

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

1 reference

12 December 2020

Identifiers

DOI

10.1200/PO.18.00122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30603737%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1 reference